Modality
Multispecific
MOA
ALKi
Target
AuroraA
Pathway
PD-1/PD-L1
Myelofibrosis
Development Pipeline
Preclinical
Nov 2023
→ Apr 2025
PreclinicalCurrent
NCT07305377
172 pts·Myelofibrosis
2023-11→2025-04·Completed
172 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-04-1711mo agoInterim· Myelofibrosis
2026-08-104mo awayOrphan Drug· Myelofibrosis
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3
Preclinical
Complet…
Catalysts
Interim
2025-04-17 · 11mo ago
Myelofibrosis
Orphan Drug
2026-08-10 · 4mo away
Myelofibrosis
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07305377 | Preclinical | Myelofibrosis | Completed | 172 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA |